Microsoft word - final list marked up - 01.07.03.doc

SCHEDULE 1
PROHIBITED SUBSTANCES
Where a Prohibited Substance (as listed below) is capable of being produced by the body naturally, a sample will be deemed to be positive where the concentration of the Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the athlete’s body tissues or fluids so exceeds, or deviates from, the range of values normally found in humans so as not to be consistent with normal endogenous production. A sample may not be regarded as positive for a Prohibited Substance in any such case where the athlete proves by clear and convincing evidence that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the athlete’s body tissues or fluids is attributable to a pathological or physiological condition. Evidence from metabolic profiles and/or the measurement of isotopic ratios (isotope ratio mass spectrometry) may be used to draw definitive conclusions as to the exogenous origin of a Prohibited Substance or its metabolites.
(a) Anabolic

dehydrochlormethyltestosterone norbolethone and chemically or pharmacologically related compounds and precursors. * In the case of a suspicious finding for testosterone, it is mandatory that a further investigation be conducted in accordance with the IAAF T/E Protocol before the *The definition of a positive finding for salbutamol as an anabolic agent is one in which the concentration of non-sulphated salbutamol in urine exceeds 1000 nanograms per millilitre. If the concentration of non-sulphated salbutamol in urine is less than 1000 nanograms per millilitre, it will be treated as a positive finding for a and chemically or pharmacologically related compounds. Peptide Hormones, Mimetics and Analogues Chorionic Gonadotrophin (hCG - human chorionic gonadotrophin – prohibited in males only): it is known that the administration to males of human chorionic gonadotrophin and other compounds with related activity can lead to an increased rate of production of endogenous androgenic steroids and is considered equivalent to the exogenous administration of testosterone. Pituitary and Synthetic Gonadotrophins (LH – prohibited in males only) Corticotrophins (ACTH, Tetracosactide): corticotrophin has been misused to increase the blood levels of endogenous corticosteroids notably to obtain the euphoric effect of corticosteroids. The application of corticotrophin is considered to be equivalent to the oral, intra-muscular or intravenous application of glucocorticosteroids (see PART I (e) below). Hormone (hGH, somatotrophin): the misuse of growth hormone in sport is deemed to be unethical and dangerous because of various adverse effects, for example, allergic reactions, diabetogenic effects, and acromegaly when applied in Recombinant Erythropoietin (r-EPO) – a sample will be deemed to be positive for r-EPO where a laboratory detects its presence in a urine sample provided by an athlete. Blood samples may be used as an aid to the detection of r-EPO, or as providing (where relevant and appropriate) corroborative evidence of its presence in a urine sample. Darbepoietin, NESP, Dynepo and any other substance which is an analogue or mimetic of these substances (or of r-EPO) is also prohibited. In such cases, the circumstances in which a sample is to be deemed to be positive, and the evidence necessary to establish this, shall be those described in the definition of r-EPO above. Insulin: permitted only to treat insulin-dependent diabetes, with written notification by an endocrinologist (for IAAF exemption procedure, see Chapter 5 above). All the respective releasing factors (and their mimetics and analogues) of the above- The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection. Where medically necessary, local and intra-articular injections of glucocorticosteroids are permitted. Aromatase inhibitors, clomifene, cyclofenil, tamoxifen - prohibited in males only. and chemically or pharmacologically related compounds * For caffeine, the definition of a positive finding is one in which the concentration in urine exceeds 12 micrograms per millilitre. A sample may not be regarded as positive for caffeine where an athlete proves by clear and convincing evidence that the elevated concentration is attributable to the athlete having an impaired caffeine metabolism condition. For cathine, the definition of a positive finding is one in which the concentration in urine exceeds 5 micrograms per millilitre. For ephedrine and methylephedrine, the definition of a positive finding is one in which the concentration in urine exceeds 10 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive finding is one in which the concentration in urine exceeds 25 micrograms per millilitre. Exceptionally, the administration of the Beta-2-agonists formoterol, salbutamol, salmeterol or terbutaline are permitted by inhalation where prescribed for therapeutic purposes by properly qualified medical personnel and where prior clearance has been given by the relevant National Federation or the IAAF in accordance with the IAAF and chemically or pharmacologically related compounds For morphine, the definition of a positive finding is one in which the concentration of free and conjugated morphine in the urine exceeds 1 microgram per millilitre unless there is a simultaneous finding of codeine or other permitted substance which may explain the finding of morphine. Substances and prohibited techniques to be detected during Peptide Hormones, Mimetics and Analogues The expression "prohibited techniques" shall include the following: Blood doping including any sort of blood transfusion or administration of red blood cell products of any origin, other than for legitimate The administration of r-EPO or other erythropoiesis-stimulating proteins (e.g. Darbepoietin, NESP, Dynepo and others) or products that enhance the uptake, transport or delivery of oxygen, e.g. modified haemoglobin products including, but not limited to, bovine and cross- linked haemoglobins, microencapsulated haemoglobin products, Masking agents and pharmacological, chemical and physical manipulation The use or attempted use of substances and/or techniques which may alter, the integrity and validity of samples used in doping controls are prohibited. Examples of masking agents: diuretics (e.g. furosemide, hydrochlorothiazide), epitestosterone*, probenecid, plasma expanders (e.g. hydroxyethylstarch). *The definition of a positive finding for epitestosterone is one in which the concentration of epitestosterone exceeds 200 ng/ml. Examples of prohibited techniques are catheterisation, urine substitution and/or tampering, inhibition of renal excretion. Gene or cell doping is defined as the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance.

Source: http://philgym.narod.ru/antidoping.pdf

<feff0050006800610072006d00480075006d0061006e

BULK PHARMACEUTICALS FOR HUMAN APPLICATION A Acetyl Salicylic Acid Acebutolol Acetylcysteine Acetazolamide Aciclovir Adapalen Adipinic Acid Aescine Albendazole Amikacine Amino Benzoic Acid Amitriptyllin Amoxicillin Sodlum sterile cryst. Amoxicillin trih compacted Amoxicillin trih micro <20 microns Amoxicillin trih powder Ampicillin anhydrous powder Ampicillin Sodium, sterile, lyoph Ampicil

Microsoft word - financial times ft

Financial Times FT.Com ( PharmaWire) Pharmawire is part of The Mergermarket Group which is a division of the Financial Times Group, publisher of the Financial Times newspaper, FT.com, Expansion and FT Deutchsland. The FT Group is a division of Pearson plc, the international media group. Roche: Boniva patent prosecution history and repeated challenges on biphosphonate class expected to

© 2010-2018 PDF pharmacy articles